Author

A. Riccio

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 4 Organism:human· 4 Research Focus:drug response / drug discovery· 2 Assay:bulk RNA-seq· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Rossi· 5 shared M. G. Santoro· 5 shared S. Piacentini· 3 shared S. Santopolo· 3 shared A. M. Anastasi· 2 shared A. Rosi· 2 shared C. Chiapparino· 2 shared C. Viollet· 2 shared

Activity by Year

2021-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

A. Rossi

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Human coronaviruses activate and hijack the proteostasis guardian HSF1 to enhance viral replication

S. Pauciullo, A. Riccio, A. Rossi, S. Santopolo, S. Piacentini, M. G. Santoro

This study shows that human coronaviruses activate HSF1 to enhance replication, suggesting HSF1 as a potential antiviral target.

bioRxiv · Dec 22, 2022 · PreprintMicrobiology

The FDA-approved drug nitazoxanide is a potent inhibitor of human seasonal coronaviruses acting at postentry level: effect on the viral spike glycoprotein

S. Piacentini, A. Riccio, S. Santopolo, S. Pauciullo, S. La Frazia, A. Rossi, J.-F. Rossignol, M. G. Santoro

The paper shows nitazoxanide inhibits seasonal coronaviruses by interfering with spike glycoprotein maturation, not affecting viral entry.

bioRxiv · Jul 13, 2022 · PreprintMicrobiology

Spike mutation resilient scFv76 antibody counteracts SARS-CoV-2 lung damage upon aerosol delivery

F. M. Milazzo, A. Chaves-Sanjuan, O. Minenkova, D. Santapaola, A. M. Anastasi, G. Battistuzzi, C. Chiapparino, A. Rosi, E. Merlo Pich, C. Albertoni, E. Marra, L. Luberto, C. Viollet, L. G. Spagnoli, A. Riccio, , R. De Santis

The paper shows that scFv76 antibody neutralizes multiple SARS-CoV-2 variants and reduces lung damage in mice when delivered via aerosol.

bioRxiv · May 27, 2022Microbiology

Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy

O. Minenkova, D. Santapaola, F. M. Milazzo, A. M. Anastasi, G. Battistuzzi, C. Chiapparino, A. Rosi, G. Gritti, G. Borleri, A. Rambaldi, C. Dental, C. Viollet, B. Pagano, L. Salvini, E. Marra, , R. De Santis

This study identifies human antibody fragments that neutralize SARS-CoV-2 variants and show efficacy in animal models, suggesting potential for early COVID-19 therapy.

bioRxiv · Jun 4, 2021Bioengineering

Impairment of SARS-CoV-2 spike-glycoprotein maturation and fusion-activity by nitazoxanide: an effect independent of spike variants emergence

A. Riccio, S. Santopolo, A. Rossi, S. Piacentini, J.-F. Rossignol, M. G. Santoro

This study shows nitazoxanide impairs SARS-CoV-2 spike maturation and fusion activity, effective against multiple variants including Delta.

bioRxiv · Apr 12, 2021Microbiology